

## ABSTRACT OF THE DISCLOSURE

Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine  
5 formulations are disclosed which are useful in prophylactic or therapeutic vaccine  
and/or gene therapy-based applications. These adjuvants comprise a block copolymer  
and a cationic surfactant component. The inclusion of a cationic surfactant results in  
an increased percentage of polynucleotide that is physically associated with the  
adjuvant *in vitro*, resulting in enhanced *in vivo* immune responses to polynucleotide  
10 vaccines.

05082704-06201  
T02290-402290